FOLH1 and prostate cancer: In the particular case of prostate cancer, WB-MRI and PET/CT with new tracers (Ga-prostate-specific membrane antigen [PSMA], 18F-fluciclovine, etc.)improve the assessment of both the extent of metastatic dissemination and the response to systemic treatments [21].